<DOC>
	<DOCNO>NCT00299026</DOCNO>
	<brief_summary>The clinical investigation international , prospective , double-blind , randomized safety efficacy study . The purpose study evaluate safety performance NIRx ( TM ) Paclitaxel-Coated Stent ( 1.0µg/mm2 paclitaxel incorporate slow- moderate-release formulation triblock copolymer carrier system ) patient present stenting de novo lesion native coronary artery .</brief_summary>
	<brief_title>A Randomized , Double-Blind , Controlled Study Safety Performance NIRx™ Paclitaxel-Coated Conformer Coronary Stent</brief_title>
	<detailed_description>The primary objective study evaluate safety performance coronary artery stenting NIRx ( TM ) Paclitaxel-Coated Stent ( 1.0µg/mm2 paclitaxel incorporate slow- moderate-release formulation triblock copolymer carrier system ) treatment de novo lesion native vessel . Patients 2 sequential cohort randomise receive either NIRx ( TM ) Paclitaxel-Coated Stent uncoated control stent . In cohort 1 , slow-release formulation NIRx ( TM ) Paclitaxel-Coated Stent study . If safety profile acceptable , moderate-release formulation NIRx ( TM ) Paclitaxel-Coated Stent study Cohort 2 . In f 2 cohort , 133 patient treat NIRx ( TM ) paclitaxel-Coated Stent 133 uncoated control stent ( 1.1 ratio ) , total 532 patient study .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>General Patient &gt; = 18 year old . Eligible percutaneous transluminal coronary angioplasty ( PTCA ) . Patient ( legal guardian ) understand study requirement stent treatment procedure provide write Informed Consent studyspecific test procedure perform . Willing comply specify followup evaluation . Documented stable angina pectoris ( Canadian Cardiovascular Society Classification [ CCS ] 1 , 2 , 3 , 4 ) , unstable angina pectoris document ischemia ( Braunwald Class IB C , IIB C , IIIB C ) , document silent ischemia . Acceptable candidate CABG . Angiographic Target lesion locate within native coronary vessel . Target lesion de novo ( i.e. , coronary lesion previously treat ) . Target lesion diameter stenosis &gt; = 50 % &lt; = 99 % ( visual estimate online QCA ) . Target lesion &lt; = 12 mm length ( visual estimate online QCA ) . Target vessel &gt; = 3.0 mm &lt; = 3.5 mm diameter ( visual estimate online QCA ) . General Known sensitivity paclitaxel . Patient receive paclitaxel antimitogenic agent within 12 month prior plan enrollment study . Patient previous stent procedure drugcoated drugeluting stent device . Patient undergone coronary intervention within 30 day prior stent placement associate protocol . Patient anticipate plan additional intervention ( staged procedure ) nontarget coronary vessel within 45 day stent placement associate protocol . MI within 72 hour plan stent placement . Left ventricular ejection fraction ( LVEF ) &lt; 30 % . Stroke within past 6 month . Acute chronic renal dysfunction ( creatinine &gt; 1.7 mg/mL &gt; 150 µmol/L ) . Acetylsalicylic acid and/or clopidogrel and/or ticlopidine contraindicate . Leukopenia ( leukocytes &lt; 3.5 x 109/liter ) . Thrombocytopenia ( platelet &lt; 100,000/mm3 ) . Active peptic ulcer active gastrointestinal ( GI ) bleeding . Known allergy stainless steel . Previously enrol NIRx ( TM ) Coronary Stent Clinical Safety Performance Study . Currently enrol another investigational device drug study complete required followup period , complete studyrequired followup less 30 day prior enrollment study . Patient lactating , positive pregnancy test within 7 day plan stent placement , intend become pregnant study ( applies female patient childbearing potential ) . Life expectancy le 24 month medical condition . Comorbid condition ( ) could limit patient 's ability participate study comply followup requirement comorbid condition ( ) could impact scientific integrity study . Angiographic Unprotected leave main coronary artery disease ( obstruction great 50 % leave main coronary artery protect least 1 nonobstructed bypass graft leave anterior descend [ LAD ] circumflex artery branch thereof ) . Target lesion previously stented segment . Target vessel treat directional coronary atherectomy , laser , transluminal extraction catheter prior stent placement . Target lesion ostial location ( within 3 mm vessel origin ) . Target site stent placement side branch &gt; 2.0 mm diameter . Target lesion severely calcify ( visual estimate ) Target vessel close abruptly threatening closure . Target lesion locate within immediately distal &gt; 60° bend vessel . Target vessel diffuse disease require one 15 mm stent full lesion coverage . Target lesion involve bifurcation branch vessel great 2.0 mm diameter originate ( either stenosis main vessel major branch stenosis major branch ) . Target lesion excessive tortuosity unsuitable stent delivery deployment . Target lesion locate within saphenous vein bypass graft . Target lesion locate vessel section supply distal graft .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Percutaneous Coronary Intervention</keyword>
	<keyword>Stent Implant</keyword>
	<keyword>Drug-coated Stent</keyword>
</DOC>